However, the winding road leading to the introduction of TRAIL-R agonists in clinical trials, has been marked by several potholes: insufficient agonistic activity of the drug, TRAIL resistance within primary cancer cells and the lack of suitable biomarkers to stratify patients prior to TRAIL-R agonist therapy [50, 55–57]. The gene discussed is TNFSF10; the disease is cancer.